Clinical Trial News and Research

RSS

Weill Cornell scientists reveal how XBP1 gene can trigger immune responses against ovarian tumors

Ovarian cancer shuts down immune system cells that would otherwise act as a first line of defense against the deadly tumor, Weill Cornell Medical College scientists report today. But a therapy that restores the cells' disease-fighting abilities could provide a powerful new strategy to attack the cancer, which kills more than 14,000 women each year.

12 Jun 2015

Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

Tioga Pharmaceuticals, a clinical stage biotechnology company, today announced the initiation of a Phase 2 clinical study of asimadoline, a novel, well-studied kappa-opioid receptor specific agonist, for the treatment of pruritus or itching. The double-blind, placebo-controlled clinical study is designed to evaluate the safety, tolerability, and clinical efficacy of asimadoline in patients with pruritus due to atopic dermatitis and is being conducted at 20 clinical study centers in the United States.

11 Jun 2015

Monteris Medical's NeuroBlate System wins Gold 2015 Medical Design Excellence Award

Monteris Medical today announced that its NeuroBlate System, a minimally invasive robotic laser thermotherapy tool for treating neurological lesions, has been selected as a gold winning product in the "Surgical Equipment, Instruments, and Supplies" category of the 2015 Medical Design Excellence Awards.

11 Jun 2015

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

This week, Lancet Oncology reports results of a 1,093-person phase III clinical trial of the drug necitumumab (IMC-11F8) combined with chemotherapies gemcitabine and cisplatin against stage IV squamous non-small cell lung cancer. With addition of necitumumab, median overall survival was 11.5 months compared with median survival of 9.9 months with the two chemotherapies alone.

11 Jun 2015

Paediatric outpatient study compares effectiveness of three alternative treatments for type 1 diabetes

A Montréal research team, co-supervised by Dr. Rémi Rabasa-Lhoret from the IRCM and Dr. Laurent Legault from the Montreal Children's Hospital, undertook the first paediatric outpatient study to compare three alternative treatments for type 1 diabetes.

11 Jun 2015

Research progress with promising Alzheimer's drug Xanamem

Actinogen Limited (Actinogen Medical, ASX: ACW), an Australian biotechnology company focused on the development of novel treatments for Alzheimer’s disease and other major age-related neurodegenerative disorders, is pleased to announce that it has received ethics approval to initiate the third and final stage of the second Phase I trial of its lead Alzheimer’s drug candidate, Xanamem™.

11 Jun 2015

UC San Diego researchers launch clinical trial to evaluate safety, efficacy of suramin drug for autism

Researchers at the University of California, San Diego School of Medicine have launched a clinical trial to investigate the safety and efficacy of an unprecedented drug therapy for autism.

11 Jun 2015

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen today announced that the Company will discuss the data supporting the Repatha (evolocumab) Biologics License Application (BLA) for the treatment of high cholesterol with the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC).

10 Jun 2015

Non-invasive accupoint electrical stimulation to treat Crohn's disease

An oral abstract presented at the International Neuromodulation Society 12th World Congress today unveiled a new collaboration between U.S. and Chinese into non-invasive accupoint electrical stimulation in Crohn's disease.

10 Jun 2015

LEO Pharma reports encouraging data from PSO-FAST clinical trial of Enstilar for psoriasis treatment

LEO Pharma A/S today announced that new data being presented at the 23rd World Congress of Dermatology shows aerosol foam Enstilar® (calcipotriol/betamethasone dipropionate 50 micrograms/g / 0,5 mg/g), the Company's dual-action investigational aerosol foam for the treatment of psoriasis vulgaris, provided rapid itch relief and improvements in itch-related sleep loss for patients suffering from psoriasis.

10 Jun 2015

INS announces winners of inaugural best abstract competition at 12th World Congress

The International Neuromodulation Society (INS) announced winners today of its inaugural best abstract competition at the 12th World Congress in Montreal.

10 Jun 2015

Lynden International selects Cryoport as preferred cryogenic logistics provider

Cryoport, Inc., the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, animal health, and reproductive medicine, today announced that it has been selected by Lynden International as its preferred provider to support cold chain clinical trial logistics for underrepresented diseases in Africa.

10 Jun 2015

CTI BioPharma amends its existing loan agreement with Hercules Technology Growth Capital

CTI BioPharma Corp. today announced that it has amended its existing loan agreement with Hercules Technology Growth Capital, Inc. (Hercules). Pursuant to the amendment, Hercules agreed to provide term loans in an aggregate principal amount of up to $25.0 million under the facility, inclusive of amounts outstanding immediately prior to closing of the amendment.

10 Jun 2015

FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

OncoGenex Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has agreed to the Company's proposed amendment to the Phase 3 AFFINITY protocol and statistical analysis plan.

10 Jun 2015

$Full clinical trial feasible in refractory chronic angina pectoris$

Full clinical trial feasible in refractory chronic angina pectoris

Results of the world's first publicly funded randomized controlled clinical trial of spinal cord stimulation, being presented today at the 12th World Congress of the International Neuromodulation Society, conclude that a fully powered clinical trial is feasible in refractory chronic angina pectoris, a disabling and persistent chronic pain condition.

10 Jun 2015

CHIMES-E study: NeuroAiD provides long-term benefits to patients after ischemic stroke

Moleac is pleased to announce the release of the CHIMES-E study results published online in the journal Cerebrovascular Diseases. It provides convincing data on NeuroAiD which confirm its persistent long-term benefits on patients' recovery after an ischemic stroke.

10 Jun 2015

BerGenBio begins BGB324 Phase 1b trial in combination with erlotinib in NSCLC patients

BerGenBio AS, an oncology biopharmaceutical company, today announces that its multi-centre open label Phase 1b trial (BGBC004) of BGB324, a selective inhibitor of Axl, in patients with Stage IIIb and Stage IV non-small cell lung cancer (NSCLC) in erlotinib-sensitive and refractory patients who have an activating EGFR mutation, is now underway at the University of Texas MD Anderson Cancer Center, Houston, Oncology Partners, Houston, and at UT Southwestern Medical Center, Dallas, Texas, USA.

10 Jun 2015

Study examines whether children born by C-section face risk of chronic diseases later in life

A new paper in the British Medical Journal by Jan Blustein, M.D., Ph.D., of New York University's Wagner School and a professor of Medicine and Population Health at NYU School of Medicine and Jianmeng Liu, M.D., Ph.D., of Peking University examines the evidence as to whether newborns delivered by Cesarean section are more likely to develop chronic diseases later in life.

10 Jun 2015

Creighton researcher receives NIH grant to study gene, stem cell therapy in coronary artery bypass grafts

A Creighton University researcher has received a National Institutes of Health grant to study the effects of gene and stem cell therapy in coronary artery bypass grafts, a first-of-its-kind undertaking that could transform the procedure, increase survival rates and dramatically reduce the possibility of re-occlusion of the grafted arteries and veins in the procedure.

10 Jun 2015

Massey researchers aim to develop models that can predict complications from stem cell transplantation

Researchers at VCU Massey Cancer Center's Bone Marrow Transplant Program have recently published findings from a phase 2 clinical trial that demonstrate lymphocyte recovery in related and unrelated stem cell transplant recipients generally falls into three patterns that are significantly associated with survival.

10 Jun 2015

Clinical Trial News and Research

Weill Cornell scientists reveal how XBP1 gene can trigger immune responses against ovarian tumors

Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

Monteris Medical's NeuroBlate System wins Gold 2015 Medical Design Excellence Award

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

Paediatric outpatient study compares effectiveness of three alternative treatments for type 1 diabetes

Research progress with promising Alzheimer's drug Xanamem

UC San Diego researchers launch clinical trial to evaluate safety, efficacy of suramin drug for autism

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Non-invasive accupoint electrical stimulation to treat Crohn's disease

LEO Pharma reports encouraging data from PSO-FAST clinical trial of Enstilar for psoriasis treatment

INS announces winners of inaugural best abstract competition at 12th World Congress

Lynden International selects Cryoport as preferred cryogenic logistics provider

CTI BioPharma amends its existing loan agreement with Hercules Technology Growth Capital

FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

Full clinical trial feasible in refractory chronic angina pectoris

CHIMES-E study: NeuroAiD provides long-term benefits to patients after ischemic stroke

BerGenBio begins BGB324 Phase 1b trial in combination with erlotinib in NSCLC patients

Study examines whether children born by C-section face risk of chronic diseases later in life

Creighton researcher receives NIH grant to study gene, stem cell therapy in coronary artery bypass grafts

Massey researchers aim to develop models that can predict complications from stem cell transplantation

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer